Interaction Checker

Gefitinib etkileşimleri

Gefitinib (Iressa) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 108 belgelenmiş etkileşim var: 8 majör, 100 orta, 0 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 0 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Majör etkileşimler (8)

  • Dekslansoprazolproton pompası inhibitörüMajör

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (Gefitinib etiketi, İlaç etkileşimleri)

  • Esomeprazolproton pompası inhibitörüMajör

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (Gefitinib etiketi, İlaç etkileşimleri)

  • Lansoprazolproton pompası inhibitörüMajör

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (Gefitinib etiketi, İlaç etkileşimleri)

  • Naproksen ve esomeprazolNSAİİMajör

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (Gefitinib etiketi, İlaç etkileşimleri)

  • Omeprazolproton pompası inhibitörüMajör

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (Gefitinib etiketi, İlaç etkileşimleri)

  • Omeprazol ve sodyum bikarbonatproton pompası inhibitörüMajör

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (Gefitinib etiketi, İlaç etkileşimleri)

  • Pantoprazolproton pompası inhibitörüMajör

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (Gefitinib etiketi, İlaç etkileşimleri)

  • Rabeprazolproton pompası inhibitörüMajör

    • Drugs Affecting Gastric pH: Avoid concomitant use of IRESSA with proton pump inhibitors, if possible. (Gefitinib etiketi, İlaç etkileşimleri)

Orta düzey etkileşimler (100)

  • AmiodaronantiaritmikOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • Amitriptilintrisiklik antidepresanOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • Amoksapintrisiklik antidepresanOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • Antasitler (Tums, Maalox, Mylanta)Reçetesiz ürünOrta

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (Gefitinib etiketi, İlaç etkileşimleri)

  • AprepitantCYP3A4 inhibitörüOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • ArmodafinilMSS uyarıcısıOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • AtazanavirantiretroviralOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • BosentanCYP3A4 indükleyicisiOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • BupropionantidepresanOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • DarunavirantiretroviralOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • Darunavir ve kobisistatantiretroviralOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • Deferasiroksdemir takviyesiOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • DeksametazonkortikosteroidOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • Desipramintrisiklik antidepresanOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • DesvenlafaksinSNRIOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • Diltiazemkalsiyum kanal blokeriOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • Doksepintrisiklik antidepresanOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • DronedaronantiaritmikOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • DuloksetinSNRIOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • EfavirenzantiretroviralOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • Efavirenz, lamivudin ve tenofovirantiretroviralOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • Elvitegravir, kobisistat, emtrisitabin ve tenofovirantiretroviralOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • Eritromisinmakrolid antibiyotikOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • EslikarbazepinantikonvülsanOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • EssitalopramSSRIOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • EtravirinantiretroviralOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • EverolimusimmünosüpresanOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • FamotidinH2 blokeriOrta

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (Gefitinib etiketi, İlaç etkileşimleri)

  • FenelzinMAO inhibitörüOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • FenitoinantikonvülsanOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • FenobarbitalbarbitüratOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • Fentermin ve topiramatMSS uyarıcısıOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • Flukonazolazol antifungalOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • FluoksetinSSRIOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • FluvoksaminSSRIOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • FosamprenavirantiretroviralOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • FosaprepitantCYP3A4 inhibitörüOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • FosfenitoinantikonvülsanOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • GriseofulvinantifungalOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • İbuprofen ve famotidinNSAİİOrta

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (Gefitinib etiketi, İlaç etkileşimleri)

  • İmatinibCYP3A4 inhibitörüOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • İmipramintrisiklik antidepresanOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • İtrakonazolazol antifungalOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • İvakaftorCYP3A4 inhibitörüOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • İzoniazidantibiyotikOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • KarbamazepinantikonvülsanOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • Ketokonazolazol antifungalOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • Klaritromisinmakrolid antibiyotikOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • KlobazambenzodiazepinOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • Klomipramintrisiklik antidepresanOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • LenakapavirantiretroviralOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • LevomilnasipranSNRIOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • Lopinavir ve ritonavirantiretroviralOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • LorlatinibCYP3A4 indükleyicisiOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • MifepristonCYP3A4 inhibitörüOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • Mirabegronbeta adrenerjik agonistOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • MirtazapinantidepresanOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • MitapivatCYP3A4 indükleyicisiOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • MitotanCYP3A4 indükleyicisiOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • ModafinilMSS uyarıcısıOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • Nafsilinpenisilin antibiyotikOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • Naltrekson ve bupropionopioid antagonistiOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • NefazodonantidepresanOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • NevirapinantiretroviralOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • Nirmatrelvir ve ritonavirantiviralOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • NizatidinH2 blokeriOrta

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (Gefitinib etiketi, İlaç etkileşimleri)

  • Nortriptilintrisiklik antidepresanOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • OkskarbazepinantikonvülsanOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • Olanzapin ve fluoksetinantipsikotikOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • PalbosiklibCYP3A4 inhibitörüOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • ParoksetinSSRIOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • PerampanelantikonvülsanOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • Posakonazolazol antifungalOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • PrimidonantikonvülsanOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • Protriptilintrisiklik antidepresanOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • RanitidinH2 blokeriOrta

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (Gefitinib etiketi, İlaç etkileşimleri)

  • RanolazinQT aralığını uzatan ilaçOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • RifabutinantibiyotikOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • RifampisinantibiyotikOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • RifapentinantibiyotikOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • RitonavirantiretroviralOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • SenobamatantikonvülsanOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • SertralinSSRIOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • SiklosporinimmünosüpresanOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • SimetidinH2 blokeriOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • SitalopramSSRIOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • Sodyum bikarbonatantasitOrta

    Drugs Affecting Gastric pH Drugs that elevate gastric pH (e.g., proton pump inhibitors, histamine H 2 -receptor antagonists, and antacids) may reduce plasma concentrations of gefitinib. (Gefitinib etiketi, İlaç etkileşimleri)

  • Suvoreksantsedatif-hipnotikOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • SuzetrijinCYP3A4 indükleyicisiOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • Tikagrelorantitrombosit ilaçOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • TopiramatantikonvülsanOrta

    • CYP3A4 Inducer: Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer. (Gefitinib etiketi, İlaç etkileşimleri)

  • TranilsiprominMAO inhibitörüOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • TrazodonantidepresanOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • Trimipramintrisiklik antidepresanOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • VarfarinantikoagülanOrta

    • Hemorrhage in patients taking warfarin: Monitor changes in prothrombin time or INR. (Gefitinib etiketi, İlaç etkileşimleri)

  • VenlafaksinSNRIOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • Verapamilkalsiyum kanal blokeriOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • VilazodonSSRIOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

  • Vorikonazolazol antifungalOrta

    • CYP3A4 Inhibitor: Monitor adverse reactions if concomitant use with IRESSA. (Gefitinib etiketi, İlaç etkileşimleri)

  • VortioksetinantidepresanOrta

    Increase IRESSA to 500 mg daily in patients receiving a strong CYP3A4 inducer (e.g., rifampicin, phenytoin, or tricyclic antidepressant) and resume IRESSA at 250 mg 7 days after discontinuation of the strong inducer [see Dosage and Administration (2.4) , Clinical Pharmacology (12.3) ] . (Gefitinib etiketi, İlaç etkileşimleri)

Kullandığınız her şeyi Gefitinib ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.